RDIF/Landsteiner To Supply 32 million Doses Of Vaccine To Mexico

Last Updated on 4 months by News Admin

Moscow, September 9, 2020 – The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and Landsteiner Scientific pharmaceutical company have announced an agreement for the supply of 32 million doses of the Russian Sputnik V vaccine to Mexico (25% of population). Deliveries are expected to start in November 2020 subject to approval by Mexico’s regulators.

As part of the agreement with RDIF, Landsteiner Scientific as a partner of RDIF would distribute the vaccine in Mexico.

On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against COVID-19 based on human adenoviral vectors platform. Detailed information on the Sputnik V vaccine, the technological platform of human adenoviral vectors, and other details are available at sputnikvaccine.com

On September 4, a research paper on the results of Phase I and Phase II clinical trials of the Sputnik V vaccine was published in one of the leading international medical journals The Lancet. Phase I and Phase II trials demonstrated no serious adverse events and a stable immune response in 100% of participants.

Post-registration clinical trials of Sputnik V vaccine involving 40,000 volunteers are currently ongoing. First results of these trials are expected to be published in October-November 2020.

Health safety of the human adenovirus vaccines has been proven by more than 75 international publications and 250 clinical trials showing greater safety track record of human adenoviral vectors versus novel unproven technologies such as monkey adenoviral vectors or mRNA.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“Our Mexican partners clearly understand the advantage of the Russian vaccine Sputnik V compared to other vaccine candidates. In particular, they highlight a much greater safety track record of human adenoviral vectors versus novel technologies such as monkey adenoviral vectors or mRNA. Safety of human adenoviral vectors used in Sputnik V has been proven over decades in over 250 clinical studies as human adenovirus has been shown to be the safest and the most “organic for humans” vaccine delivery mechanism as human adenovirus coexists with humans for over 100,000 years. Unlike for well studied human adenoviral vector there were no long term studies for novel vaccines based on mRNA and monkey adenovirus. That is why a recent survey revealed that 66% of Mexicans express confidence in the Russian vaccine. We have agreed to deliver the large batch of Sputnik V vaccine to Mexico which will help 25% of the Mexican population to receive access to the safe and effective vaccine”. PR

Recommended For You

About the Author: News Admin

NEWS784 was founded in November 2015. We welcome press releases, photos, news tips and story ideas. Contact: news784svg@gmail.com WhatsApp: 496 2450